- Home
- ESQ vs GERN Comparison
ESQ vs GERN Comparison
Compare ESQ & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESQ | GERN |
|---|---|---|
| Founded | 2006 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 1.1B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ESQ | GERN |
|---|---|---|
| Price | $105.20 | $1.29 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $120.33 | $2.17 |
| AVG Volume (30 Days) | 91.6K | ★ 15.7M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 14.20 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.15 | $26.91 |
| Revenue Next Year | $39.09 | $43.75 |
| P/E Ratio | $75.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $87.54 | $1.04 |
| 52 Week High | $119.86 | $2.01 |
Technical Indicators
Market Signals| Indicator | ESQ | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 32.86 |
| Support Level | $104.58 | $1.24 |
| Resistance Level | $111.41 | $1.49 |
| Average True Range (ATR) | 2.47 | 0.09 |
| MACD | -0.28 | -0.02 |
| Stochastic Oscillator | 24.78 | 0.00 |
Price Performance
Historical ComparisonAbout ESQ Esquire Financial Holdings Inc.
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.